Drugs / Radafaxine
Radafaxine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00057213 | Mar 2003 → Apr 2007 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00057226 | Mar 2003 → Apr 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00057239 | Mar 2003 → May 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radafaxine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057213 ↗ |
| Known as | GW-353162A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1172928 ↗ |
| Known as | Radafaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1172928 ↗ |
| Known as | Radafaxine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1172928 ↗ |
| Known as | RADAFAXINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1172928 ↗ |
| Modality | Small molecule | — CHEMBL1172928 ↗ |